Home
Trading Tools
Market Screeners
Cryptocurrencies
- Crypto Exchanges
Markets Insight
My Account
- Sign Up Biedex Ventures Studio
- Login Biedex Ventures Studio

Menu

Home
Trading Tools
Market Screeners
Cryptocurrencies
- Crypto Exchanges
Markets Insight
My Account
- Sign Up Biedex Ventures Studio
- Login Biedex Ventures Studio

Home
Trading Tools
Market Screeners
Cryptocurrencies
- Crypto Exchanges
Markets Insight
My Account
- Sign Up Biedex Ventures Studio
- Login Biedex Ventures Studio

Menu

Home
Trading Tools
Market Screeners
Cryptocurrencies
- Crypto Exchanges
Markets Insight
My Account
- Sign Up Biedex Ventures Studio
- Login Biedex Ventures Studio

H.
- Biedex Markets Unlocking the Power of Investing
- Deal Sourcing
BIBANQ
Business Challenges
Company
- About
- Team
- Careers
- Why us
Case studies
Biedex Markets News
Resources
Contact
Client Support
Banks & Insurance
Reg A raise

Menu

H.
- Biedex Markets Unlocking the Power of Investing
- Deal Sourcing
BIBANQ
Business Challenges
Company
- About
- Team
- Careers
- Why us
Case studies
Biedex Markets News
Resources
Contact
Client Support
Banks & Insurance
Reg A raise

DNAdamaging

Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference - Entera Bio (NASDAQ:ENTX)

ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)

Premium Features

Biedex Research Terminal
Trading Signals Centre
The Ultimate Markets Research Terminal
AI-Powered Calendar Tool
Stock Market Insight

Biedex Research Terminal
Trading Signals Centre
The Ultimate Markets Research Terminal
AI-Powered Calendar Tool
Stock Market Insight

Stock Market Insight
Stock Market Analysis & Tools
Fund Research
ETF Research
Dow Jones News Squawk

Stock Market Insight
Stock Market Analysis & Tools
Fund Research
ETF Research
Dow Jones News Squawk

More Services

Deal Sourcing
Biedex Ventures Studio
BIBANQ
Wealth Management
AI-Powered Calendar Tool

Deal Sourcing
Biedex Ventures Studio
BIBANQ
Wealth Management
AI-Powered Calendar Tool

Login
Account
Biedex Markets Premium
Login Biedex Ventures Studio
Sign Up Biedex Ventures Studio

Login
Account
Biedex Markets Premium
Login Biedex Ventures Studio
Sign Up Biedex Ventures Studio

I agree to the Privacy Policy and give my permission to process my personal data for the purposes specified in the Privacy Policy.

Biedex Markets Limited

34-35 Hatton Garden Holborn
London EC1N 8DX.
Phone:+44 (0)2034322962

E: [email protected]

Client Support
Contact

Menu

Client Support
Contact

© 2024

by Biedex Markets Limited. A Biedex Ventures LIMITED Company London UK

Cookie Policy (EU)
Privacy Statement (EU)
Impressum
Cookie Policy (UK)
Privacy Statement (UK)
Cookie Policy (US)
Privacy Statement (US)
Disclaimer

Cookie Policy (EU)
Privacy Statement (EU)
Impressum
Cookie Policy (UK)
Privacy Statement (UK)
Cookie Policy (US)
Privacy Statement (US)
Disclaimer

Legal Notice: This site is not intended to provide any investment, financial, legal, regulatory, accounting, tax or similar advice, and nothing on this site should be construed as a recommendation by Biedex Ventures LIMITED (“Biedex Ventures”), its affiliates, or any third party, to acquire or dispose of any investment or security, or to engage in any investment strategy or transaction. An investment in any strategy involves a high degree of risk and there is always the possibility of loss, including the loss of principal. Nothing in this site may be considered as an offer or solicitation to purchase or sell securities or other services. Alternative investments in private placements are highly illiquid, speculative, and involve a high degree of risk. Past performance is not indicative of future results. Investors may not get back their money originally invested and those who cannot afford to lose their entire investment should not invest. Prior to investing, carefully consider the respective fund documentation for details about potential risks, charges, and expenses. The value of an investment may go down as well as up. An investment in a private equity (“PE”) fund or investment vehicle is not the same as a deposit with a banking institution. Investors receive illiquid and/or restricted membership interests that may be subject to holding period requirements and/or liquidity concerns. Investors who cannot hold an investment for the long term (at least 10 years) should not invest. In the most sensible investment strategy for PE investing, PE should only be part of your overall investment portfolio. The PE portion of your portfolio may include a balanced portfolio of different PE funds Investors must be accredited to receive investment opportunities from Biedex Ventures. Many of our investments will be limited to Qualified Clients and Qualified Purchasers. Funds offered on this site are sec exempt funds, the Pooled Investment Vehicles Under Section 3(c)(1) of the Investment Company Act of 1940. Funds are managed by BIEDEX VENTURES CAPITAL MANAGEMENT, LLC. An ERA, registerd with FINRA in the USA. Biedex Markets is not a crowdfundig platform. Biedex Markets is an intermediary platform that matches investors with founders, helps startups prepare for fundraising, and helps investors analyze investment opportunities in private equity.

top

Simplifying IT
for a complex world.

About us
Why us
Team
Careers

About us
Why us
Team
Careers

Platform partnerships

AWS
Google Cloud
Microsoft
Salesforce

More services

Deal Sourcing
Biedex Ventures Studio
BIBANQ
Wealth Management
AI-Powered Calendar Tool

Deal Sourcing
Biedex Ventures Studio
BIBANQ
Wealth Management
AI-Powered Calendar Tool

Premium Trading Solutions

Biedex Markets Terminal

Trading Signals Centre

Economic AI Calendar

Asset Analysis

More Premium Tools

The Ultimate Markets Research Terminal
Stock Market Analysis & Tools
Fund Research
Streamlined and Unbiased ETF Research
Dow Jones News Squawk

The Ultimate Markets Research Terminal
Stock Market Analysis & Tools
Fund Research
Streamlined and Unbiased ETF Research
Dow Jones News Squawk